Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis
Phytomedicine · 2025
DOI: 10.1016/j.phymed.2025.157066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Fan Yang und 22 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pha…. Hauptthemen laut MEDLINE: Cannabidiol, Osteosarcoma, Chemokine CCL5, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, China Association for Science and Technology, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Osteosarcoma remains a therapeutic challenge due to its aggressive behavior and high metastatic potential, necessitating exploration of novel treatment modalities. Cannabidiol (CBD), a non-psychoactive phytocannabinoid with emerging anticancer properties, has shown promise in preclinical cancer models. However, its mechanisms of action in osteosarcoma remain incompletely understood. This study systematically investigates the antitumor effects of CBD on osteosarcoma and elucidates its molecular targets within the TNF-α/NF-κB/CCL5 signaling axis. METHODS: The effective concentration of CBD was determined using the CCK-8 assay. Functional assays (EdU proliferation, Transwell migration/invasion, and scratch wound healing) evaluated its impact on osteosarcoma cell malignancy. A mouse xenograft model assessed in vivo efficacy. Network pharmacology and RNA-seq identified key pathways, which were validated via ELISA, qRT-PCR, and western blot. Molecular interactions were confirmed through CETSA, SPR, ITC, and molecular docking analyses targeting p65 (NF-κB subunit). RESULTS: CBD potently suppressed osteosarcoma cell proliferation, migration, and invasion while inhibiting xenograft tumor growth in vivo. Mechanistically, CBD disrupted the TNF-α/NF-κB/CCL5 axis by directly binding p65, thereby attenuating NF-κB-mediated transcriptional activation of CCL5. Notably, CBD abrogated a p65-CCL5 positive feedback loop that perpetuates inflammatory signaling, a novel finding linking CBD's effects to inflammatory cascade disruption in osteosarcoma. CONCLUSION: This study provides the first evidence that CBD inhibits osteosarcoma progression by targeting the TNF-α/NF-κB/CCL5 axis, disrupting a coordinated inflammatory-proliferative cascade. These findings position CBD as a promising therapeutic candidate for osteosarcoma, warranting further clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Minist…
- Department of Orthopedics at the First Affiliated Hospital, Harbin Medical University, Harbin 150001, China.
- College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
- Key Lab of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
- Department of Orthopedics at the First Affiliated Hospital, Harbin Medical University, Harbin 150001, China. Electronic address: silencemadz@126.com.
- College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China. Electronic address: wangli@hrbmu.edu.cn.
Förderung
- National Key Research and Development Program of China
- China Association for Science and Technology
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
- Key Research and Development Program of Heilongjiang
Zitieren
APA
Yang, F., Duan, S., Liu, J., An, Z., Liu, W., Wang, X., Zhang, T., Liu, M., Li, F., Wu, W., Liu, Y., Tang, J., Wang, X., Xu, W., Qi, W., Liu, Y., Li, L., Li, Y., Liu, X., …, & Yang, L. (2025). Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157066
Vancouver
Yang F, Duan S, Liu J, An Z, Liu W, Wang X, et al. Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157066
BibTeX
@article{Yang2025,
author = {Yang, Fan and Duan, Shuqin and Liu, Jingwei and An, Zhechao and Liu, Wangyang and Wang, Xinyue and Zhang, Tingting and Liu, Mingyu and Li, Fengda and Wu, Wei and Liu, Yingzhe and Tang, Jianyong and Wang, Xiaojuan and Xu, Wenhui and Qi, Wenyi and Liu, Yunhe and Li, Liangliang and Li, Yuan and Liu, Xin and Yang, Baofeng and Zhang, Zheng and Wang, Li and Yang, Lei},
title = {Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis},
journal = {Phytomedicine},
year = {2025},
doi = {10.1016/j.phymed.2025.157066}
}
EUVIMED